DYN and RNA Related Headlines
Go Back- Jefferies sees Dyne as key beneficiary of Novartis’ Avidity buyout
- Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal
- RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
- Avidity Biosciences stock soars on Novartis takeover approach report
- Dyne Therapeutics Inc. (DYN) gains following Avidity Biosciences Inc. (RNA) Takeover Rumors, Up 24%
- Raymond James bullish on biotech firms on favorable valuation
